Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | ITK | Q08881 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | BUB1 | O43683 | 2/20 | 0.33 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | TTK | P33981 | 3/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30183696 | 0.96 | BRD4 (0.38) | BRD4ITKEGFRBUB1ACVR1B | |
| SCHEMBL22123367 | 0.96 | BRD4 (0.38) | BRD4ITKEGFRBUB1ACVR1B | |
| SCHEMBL30171844 | 0.94 | BRD4 (0.37) | BRD4ITKEGFRBUB1ACVR1B | |
| SCHEMBL30385261 | 0.92 | BRD4 (0.39) | BRD4ITKEGFRBUB1ACVR1B | |
| SCHEMBL22123385 | 0.92 | TTK (0.33) | PTK6TTKIRAK4 | |
| SCHEMBL22123363 | 0.92 | BRD4 (0.36) | BRD4ITKEGFRBUB1ACVR1B | |
| SCHEMBL22124583 | 0.91 | MAPKAPK5 (0.33) | PTK6TTKIRAK4 | |
| SCHEMBL30171576 | 0.91 | MAPKAPK5 (0.33) | PTK6TTKIRAK4 | |
| SCHEMBL30172091 | 0.91 | ITK (0.39) | BRD4ITKEGFRBUB1ACVR1B | |
| SCHEMBL24112570 | 0.90 | PTK6 (0.33) | PTK6TTKIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898630-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-10 | — | — | EP | disclosed |
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3898631-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| EP-3898629-B1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | BRD4 735/4885ITK 816/4885EGFR 1595/4885 |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | BRD4 735/4885ITK 816/4885EGFR 1595/4885 |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | BRD4 687/4885ITK 814/4885EGFR 1591/4885 |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IL4, RPS4Y1, RPS4X | BRD4 197/4885ITK 565/4885EGFR 1297/4885 |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, MYD88, IL1R1 | BRD4 596/4885ITK 715/4885EGFR 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.